The company said that at its Annual Meeting of Shareholders held on April 25, 2024, the nominees for the Board of Directors, including Albert Bourla, were elected to serve until the next Annual Meeting of Shareholders. Mr. Bourla received 3,416,127,786 votes for and 272,930,253 votes against.

1. 01

   The company said that at its Annual Meeting of Shareholders held on April 25, 2024, the nominees for the Board of Directors, including Albert Bourla, were elected to serve until the next Annual Meeting of Shareholders. Mr. Bourla received 3,416,127,786 votes for and 272,930,253 votes against.

2. 02

   The company said that the proposal to elect KPMG LLP as its independent registered public accounting firm for fiscal 2024 was approved, with 4,315,675,552 votes for and 256,738,678 votes against. The Amended and Restated Pfizer Inc. 2019 Stock Plan was approved with 3,405,629,196 votes for and 275,998,451 votes against.

3. 03

   The company said the advisory vote on the compensation of its Named Executive Officers was approved, with 3,360,637,251 votes for, 315,293,726 votes against and 26,256,736 abstentions.

4. 04

   The company said the shareholder proposal for an Independent Board Chair Policy was not approved, with 1,284,408,190 votes for and 2,391,266,871 votes against. The proponent withdrew the shareholder proposal to amend the Director Resignation Process, and it was not presented at the meeting.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.